| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
S23477-5mg |
99.5% | ￥770.00 | 6 | - | - | - |
|
S23477-10mg |
99.5% | ￥1290.00 | 7 | - | - | - |
|
S23477-25mg |
99.5% | ￥2200.00 | 6 | - | - | - |
|
S23477-50mg |
99.5% | ￥3190.00 | 5 | - | - | - |
|
Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer
| 產品描述： | Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | IC50: 0.33 μM (Hepsin);c-Met/HGFR | ||||||||||||||||||||
| 體外研究： | Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage. | ||||||||||||||||||||
| 體內研究： | HepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis. | ||||||||||||||||||||
| 參考文獻： | 1. Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京